ROCKVILLE, Md., May 4, 2015 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific
therapeutics focused on protecting the microbiome, as well as
treating other diseases, announced Steven
A. Shallcross has been appointed Chief Financial Officer,
Treasurer and Secretary effective June 1,
2015. He replaces C. Evan
Ballantyne who will be leaving the Company in May to pursue
other interests.
Mr. Shallcross brings to Synthetic Biologics operational,
financial and international biotech industry experience, as well as
an established track record at leading the financial development
and strategy for several publicly traded biotech companies. He
served for four years as the Chief Financial Officer and Treasurer
of Vanda Pharmaceuticals, Inc., leading the company through its
successful IPO and follow-on offering. He currently is Executive
Vice President and Chief Financial Officer of Nuo Therapeutics,
Inc. and previously served as the Senior Vice President and Chief
Financial Officer of Middlebrook Pharmaceuticals, Inc. (formerly
Advancis Pharmaceutical Corporation). Mr. Shallcross also served as
Executive Vice President and Chief Financial Officer of Innocoll AG
(formerly privately held Innocoll Holdings, Inc.), a global,
commercial-stage biopharmaceutical company specializing in the
development and commercialization of collagen based products.
"Steve's significant experience will be valuable to achieving
the next phase of Synthetic Biologics' development," said
Jeff Riley, Chief Executive Officer.
"He has effectively managed broad operations, cultivated
significant relationships with a number of corporate development
leaders in biotech, and repeatedly structured financing strategies
that enabled some very successful companies in our industry to
achieve their clinical and business goals. The Synthetic Biologics'
board and team look forward to Steve's contributions as we execute
on our clinical roadmap and seek to generate increased returns for
our shareholders. We also want to thank Evan for his dedication and
contributions during the past three years, and wish him the very
best of success in his future endeavors."
In addition to his substantial biotech industry experience, Mr.
Shallcross also held key leadership positions with a number of
other companies, including serving as the Chief Financial Officer
of Empire Petroleum Partners, LLC and Bering Truck Corporation, and
Acting Chief Financial Officer for Senseonics. He holds an MBA from
the University of Chicago's Booth
School of Business, a Bachelor of Science degree in Accounting from
the University of Illinois, Chicago,
and is a Certified Public Accountant in the State of Illinois.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage
biotechnology company developing pathogen-specific therapeutics
focused on protecting the microbiome, as well as treating other
diseases. The Company is developing an oral biologic to protect the
gut microbiome from intravenous (IV) antibiotics for the prevention
of C. difficile infection, an oral statin treatment to
reduce the impact of methane producing organisms on irritable bowel
syndrome with constipation (IBS-C), and in collaboration with
Intrexon Corporation (NYSE: XON), a monoclonal antibody combination
for the treatment of Pertussis. In addition, the Company is
developing a Phase 2 oral estriol drug for the treatment of
relapsing-remitting multiple sclerosis (MS) and cognitive
dysfunction in MS. For more information, please visit Synthetic
Biologics' website at www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic
Biologics' current expectations and projections about future
events. In some cases forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are difficult
to predict and include statements regarding the expected
contribution of Mr. Shallcross. The forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from those reflected in
Synthetic Biologics' forward-looking statements include, among
others, a failure to successfully integrate the new management and
other factors described in Synthetic Biologics' report on Form 10-K
for the year ended December 31, 2014
and any other filings with the SEC. The information in this release
is provided only as of the date of this release, and Synthetic
Biologics undertakes no obligation to update any forward-looking
statements contained in this release on account of new information,
future events, or otherwise, except as required by law.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/steven-shallcross-named-chief-financial-officer-of-synthetic-biologics-300076114.html
SOURCE Synthetic Biologics, Inc.